Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ATIC | P31939 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 6/20 | 0.47 |
| ▸ | LDHB | P07195 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039922 | 1.00 | DHODH (0.50) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL29260803 | 0.93 | DHODH (0.55) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL901598 | 0.91 | HSD17B10 (0.48) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL28261469 | 0.88 | DHODH (0.52) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL344711 | 0.88 | HSD17B10 (0.50) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL2477681 | 0.86 | HSD17B10 (0.58) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL7537511 | 0.84 | DHODH (0.52) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL31414101 | 0.83 | HSD17B10 (0.54) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL4415520 | 0.83 | HSD17B10 (0.54) | DHODHPDE10AHPGDHSD17B10THRB | |
| SCHEMBL27572021 | 0.82 | HSD17B10 (0.48) | DHODHPDE10AHPGDHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20210397090-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION AND METHOD FOR FORMING RESIST PATTERN USING THE SAME | NISSAN CHEMICAL CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| US-10336859-B2 | Method for preparing an electrolyte capacitor | TAYCA CORPORATION (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190106531-A1 | Method for preparing an electrolyte capacitor | TAYCA CORPORATION (JP) | 2019-04-11 | — | — | US | disclosed |
| US-9589738-B2 | Solid electrolyte capacitor and a method for manufacturing the same | TAYCA CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20140334066-A1 | SOLID ELECTROLYTE CAPACITOR AND A METHOD FOR MANUFACTURING THE SAME | TAYCA CORPORATION (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20050228038-A1 | 11-Beta hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/anti-diabetes compounds and 17-beta hydrosteroid dehydrogenase type I inhibitors as useful agents for the treatment of cancers, especially breast cancer | SCIENCE & TECHNOLOGY CORPORATION @ UNM | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228038-A1 | 11-Beta hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/anti-diabetes compounds and 17-beta hydrosteroid dehydrogenase type I inhibitors as useful agents for the treatment of cancers, especially breast cancer | HSD17B1, HSD11B1, HSD17B2 | DHODH 39/4885PDE10A 4297/4885HPGD 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.